Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Assets: 2013-2025

Historic Non-Current Assets for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $60.8 million.

  • Theravance Biopharma's Non-Current Assets fell 74.64% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.8 million, marking a year-over-year decrease of 74.64%. This contributed to the annual value of $193.1 million for FY2024, which is 22.28% down from last year.
  • Latest data reveals that Theravance Biopharma reported Non-Current Assets of $60.8 million as of Q3 2025, which was up 1.71% from $59.7 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Non-Current Assets registered a high of $277.2 million during Q1 2023, and its lowest value of $37.7 million during Q4 2021.
  • In the last 3 years, Theravance Biopharma's Non-Current Assets had a median value of $242.7 million in 2024 and averaged $206.2 million.
  • Per our database at Business Quant, Theravance Biopharma's Non-Current Assets surged by 573.66% in 2022 and then plummeted by 75.39% in 2025.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Non-Current Assets stood at $37.7 million in 2021, then skyrocketed by 573.66% to $253.9 million in 2022, then fell by 2.16% to $248.5 million in 2023, then fell by 22.28% to $193.1 million in 2024, then slumped by 74.64% to $60.8 million in 2025.
  • Its last three reported values are $60.8 million in Q3 2025, $59.7 million for Q2 2025, and $193.3 million during Q1 2025.